FibroGen competitors

FibroGen Competitors include Cyclacel Pharmaceuticals, Moderna Therapeutics, Rigel Pharmaceuticals and RubrYc Therapeutics.
Add company...
FibroGen
FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs.
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other serious diseases.
Moderna Therapeutics
Moderna Therapeutics
Moderna Therapeutics develops messenger RNA therapeutics that produces human proteins for antibodies inside patient cells.
Rigel Pharmaceuticals
Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
RubrYc Therapeutics
RubrYc Therapeutics
RubrYc Therapeutics is a biotechnology solutions company using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies.
Founding Date
Founding Date
1993
Founding Date
1992
Founding Date
N/A
Founding Date
1996
Founding Date
2017
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
San Francisco, US HQ
Locations
Berkeley Heights, US HQ
Dundee City, GB
Locations
Cambridge, US HQ
Huddinge, SE
Cambridge, US
Cambridge, US
Norwood, US
Chicago, US
Huntington, US
Locations
South San Francisco, US HQ
Locations
San Ramon, US HQ
Employees
Employees
4619% increase
Employees
128% decrease
Employees
6801% increase
Employees
15853% increase
Employees
N/A
Valuation ($)
Valuation ($)
4.8 b
Valuation ($)
10.8 m
Valuation ($)
6.7 b
Valuation ($)
428 m
Valuation ($)
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
2.4 k
Twitter followers
1.3 k
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$213m (FY, 2018)
Revenue (est.)
N/A
Revenue (est.)
$205.8m (FY, 2017)
Revenue (est.)
$44.5m (FY, 2018)
Revenue (est.)
N/A
Net income
Net income
($86.4m) (FY, 2018)
Net income
($7.5m) (FY, 2017)
Net income
($255.9m) (FY, 2017)
Net income
($70.5m) (FY, 2018)
Net income
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 152.2m
Total funding raised
$ 1.7b
Total funding raised
$ 130m
Total funding raised
$ 10m
For sources of this data, please see the company profileDownload Excel

View company profiles

Cyclacel Pharmaceuticals
HQ
Berkeley Heights, US
Employees
12↓ 8% decrease

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other serious diseases.

View company
Moderna Therapeutics
HQ
Cambridge, US
Employees
680↑ 1% increase

Moderna Therapeutics develops messenger RNA therapeutics that produces human proteins for antibodies inside patient cells.

View company
Rigel Pharmaceuticals
HQ
South San Francisco, US
Employees
158

Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.

View company
RubrYc Therapeutics
HQ
San Ramon, US

RubrYc Therapeutics is a biotechnology solutions company using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies.

View company